Safety considerations of fluoroquinolones in the elderly: an update.
about
New Antituberculosis Drugs: From Clinical Trial to Programmatic UseUnexpected link between an antibiotic, pannexin channels and apoptosisMoxifloxacin safety: an analysis of 14 years of clinical data.Risks associated with the therapeutic use of fluoroquinolones.Irritable bowel syndrome: a microbiome-gut-brain axis disorder?Efficacy and safety of nadifloxacin for bacterial skin infections: results from clinical and post-marketing studies.Moxifloxacin-induced acute psychosis: A case report with literature reviewRegional variation in antibiotic prescribing among medicare part D enrollees, 2013Low Concordance With Guidelines for Treatment of Acute Cystitis in Primary Care.The ciprofloxacin target AUC : MIC ratio is not reached in hospitalized patients with the recommended dosing regimens.Cefditoren versus levofloxacin in patients with exacerbations of chronic bronchitis: serum inflammatory biomarkers, clinical efficacy, and microbiological eradication.Synthesis, physiochemical properties, photochemical probe, and antimicrobial effects of novel norfloxacin analogues.Leukocytoclastic Vasculitis with Systemic Involvement Associated with Ciprofloxacin Therapy: Case Report and Review of the LiteratureElderly patients with community-acquired pneumonia: optimal treatment strategies.Cardiovascular and metabolic safety profiles of the fluoroquinolones.Levofloxacin for the treatment of pyelonephritis.Safety issues and drug-drug interactions with commonly used quinolones.Management of Inflammatory Bowel Disease in the Elderly.Antibiothérapie du sujet âgé : On peut toujours mieux faire.[Nitroxoline - an option for the antibiotic treatment of urinary tract infections].Fluoroquinolone-induced serious, persistent, multisymptom adverse effects.Potentially inappropriate medication in geriatric patients: the Austrian consensus panel list.Levofloxacin-induced seizures in a patient without predisposing risk factors: the impact of pharmacogenetics.Levofloxacin dosing regimen in severely morbidly obese patients (BMI ≥40 kg/m(2)) should be guided by creatinine clearance estimates based on ideal body weight and optimized by therapeutic drug monitoring.Effects of ciprofloxacin and quercetin on fetal brain development: a biochemical and histopathological study.A comparison of levofloxacin and oral third-generation cephalosporins as antibacterial prophylaxis in acute leukaemia patients during chemotherapy-induced neutropenia.Acute kidney injury due to ciprofloxacin for treatment of acute pyelonephritis.Incidence and outcomes of long QTc in acute medical admissionsCiprofloxacin impairs mitochondrial DNA replication initiation through inhibition of Topoisomerase 2
P2860
Q26741138-AF09C6B4-3E83-4DFD-9FBE-F75A13753BE7Q30410630-EFD2AA25-B613-418C-9A1C-1D6AE4D51C9CQ34310568-253BC6EB-A437-4C5B-84F5-9132A3AFA442Q34343391-5C72B761-1E1A-4251-801B-3004BFC4B6E1Q34366837-E98346D5-699F-4128-AA32-63BDD1407BAAQ34438041-DF3C37FB-A55D-45DA-BFEE-23912299B493Q34679755-BCEF0C78-74F1-4DE4-BE48-4CA618602C35Q36219079-33B3E901-2F82-4268-8E35-A94E00F95DDCQ36363646-E913C65E-1A9D-4FA7-AEA5-2C5CE3185FBAQ36562483-C908F7D1-B6D2-48D1-9DED-39F0069C0525Q36617992-CB15D2F1-6F4A-4251-B3C7-39F6632A642DQ37156847-492FBB01-0A52-4959-8724-925570B8533DQ37552857-BBDFF624-50C4-4790-BADF-813C6DF487A5Q37896600-E5B3A03A-7E21-4A5C-9C33-FF365D5FD04EQ37940543-B1E8F1E2-29E2-40A7-8986-FFFDAB3556F1Q38101380-BF68BE4F-2165-426E-A572-B9669743EC9BQ38271318-8BF1ADCB-6DB0-428A-8606-8DA3BE61E333Q38844393-18A5DCE5-58E2-4B7F-B009-60F5BD140CA2Q38862567-2C98ACAE-8F6D-4E39-8BF7-CC6B644AD38FQ40551285-4D79DA01-41C4-4213-9BF7-854FE03CA827Q42591462-65F85DE2-3471-4762-8332-898623A68665Q43581039-283AABA1-5BCE-412B-9166-406A44F4FF0EQ44213464-A4B07852-99B8-4934-8236-66589BA8C391Q44455948-A24251A0-7642-4C1C-B3C6-B9B88CED8DE0Q47564906-6F41E3D3-FE98-441D-9FD0-99A888A47BADQ50080905-DE206AB7-6A52-4BA2-9D6C-5DD6EB6EF744Q53971936-835962D6-EC8D-4380-899E-FBDD28BA168EQ58697738-23CADD11-800E-428C-9776-23CD72D3D8BFQ58778672-3A659863-9D44-4739-BE41-3602511D28D9
P2860
Safety considerations of fluoroquinolones in the elderly: an update.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մարտին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Safety considerations of fluoroquinolones in the elderly: an update.
@ast
Safety considerations of fluoroquinolones in the elderly: an update.
@en
Safety considerations of fluoroquinolones in the elderly: an update.
@nl
type
label
Safety considerations of fluoroquinolones in the elderly: an update.
@ast
Safety considerations of fluoroquinolones in the elderly: an update.
@en
Safety considerations of fluoroquinolones in the elderly: an update.
@nl
prefLabel
Safety considerations of fluoroquinolones in the elderly: an update.
@ast
Safety considerations of fluoroquinolones in the elderly: an update.
@en
Safety considerations of fluoroquinolones in the elderly: an update.
@nl
P2860
P1433
P1476
Safety considerations of fluoroquinolones in the elderly: an update.
@en
P2093
Hartmut Lode
Ralf Stahlmann
P2860
P304
P356
10.2165/11531490-000000000-00000
P577
2010-03-01T00:00:00Z
P6179
1032403668